Path Herbst Prog 2016 - maw.co.at · Submission of slide seminar diagnoses: 2 credits per slide...

Österreichische Gesellschaft für Pathologie/Österreichische Abteilung der IAP

Schweizerische Gesellschaft für Pathologie/Société Suisse de Pathologie

3rd Joint Annual Meeting of the Swiss and Austrian Societies of Pathology

November 10-12, 2016TechGate Vienna, Donau City Wien ©

cov

er p

ictu

re: C

hris

ta F

reib

auer

www.pathology.atwww.sgpath.ch

PROGRAMPROGRAM

Liquid Biopsy cobas® EGFR Mutation Test v2 (CE-IVD)

Real-time PCR test for EGFR mutation analysis in DNA derived from formalin-fixed paraffin-embedded tumor tissue or plasma samples.

The cobas® EGFR Mutation Test v2 CE-IVD is intended to be used as an aid in

selecting patients with NSCLC for therapy with an EGFR tyrosine kinase inhibitor.

COBAS and LIFE NEEDS ANSWERS are trademarks of Roche.© 2016 Rochewww.roche.at

1

Welcome address

Dear Colleagues

It is a great pleasure for us to welcome you all at the 3rd Joint Meeting of the Austrianand Swiss Societies of Pathology in Vienna. Following Feldkirch in 2010 and Badenin 2013, this meeting has become a valuable tradition for the pathologists of our twocountries.

At the same time the 3rd Joint Meeting is the 82nd Annual Meeting of the Swiss Society of Pathology and one of the two annual meetings of the 52-years old AustrianSociety of Pathology, the “Herbsttagung 2016”.

Joint meetings allow a scientific exchange similar to national meetings but in addition,enable personal and scientific interaction with new colleagues without the hectic paceof big international congresses.

Driven by new technologies, the field of pathology is rapidly expanding, making thepathologist increasingly the gatekeeper of clinical decision making. At the same time,conventional histopathology remains the corner stone of the diagnostic work. Thescientific committee sought to put together a program which covers the wide rangefrom conventional to evolving molecular pathology, being educational and attractivefor experienced senior pathologists as well for junior pathologists and residents.

Vienna is not only a beautiful congress place but also an attractive cosmopolitan citywith an enormous tradition, history and culture. In this respect, the 3rd Joint Meetingof the OEGP/SGPath will not be only an interesting scientific and educational meeting,but also a gorgeous meeting place and agreeable get-together for the pathologists ofour two (and other) countries.

We are looking forward to meet you all in Vienna to have a great time together.

With kind regards

Prof. Dr. Martin Klimpfinger Dr. Christa FreibauerPresident of the OEGPath / IAP Austria Secretary of the OEGPath / IAP Austria

Prof. Dr. med. Gieri Cathomas Prof. Dr. med. Zsuzsanna VargaPresident of the SGPath / SSPath Secretary of the SGPath / SSPath

SAVE THE DATE 2017

Online registration�/�Anmeldungen�/�Inscriptions www.meeting-com.ch

SWISS PATHOLOGY DAYSANNUAL CONGRESS OF THE SWISS SOCIETY OF PATHOLOGY

JAHRESTAGUNG DER SCHWEIZERISCHEN GESELLSCHAFT FÜR PATHOLOGIE

CONGRÈS ANNUEL DE LA SOCIÉTÉ SUISSE DE PATHOLOGIE

10-12.11.2017

Kultur- und Kongresszentrum Thun

Ö S T E R R E I C H I S C H E G E S E L L S C H A F T F Ü R P A T H O L O G I E /

Ö S T E R R E I C H I S C H E A B T E I L U N G D E R I A P

www.pathology.at © cover picture: Christa Freibauer

F R Ü H J A H R S T A G U N G 2 0 1 7G E M E I N S A M E F O R T B I L D U N G S T A G U N G F Ü R B I O M E D I Z I N I S C H E

A N A LY T I K E R I N N E N U N D Ä R Z T I N N E N

2 3 . - 2 5 . F E B R U A R 2 0 1 7T E C H G A T E V I E N N A , D O N A U C I T Y W I E N

4

General Information

Host OrganizationAustrian Society of Pathology / Austrian Division of the InternationalAcademy of Pathology (OEGPath/IAP Austria); www.pathology.at represented by:Prim. Univ.-Prof. Dr. Martin Klimpfinger, PresidentPathologisch-Bakteriologisches Institut, SMZ-Süd - Kaiser-Franz-Josef Spitalmit Gottfried von Preyer’schem Kinderspital, Kundratstraße 3, 1100 WienandSwiss Society of Pathology (SGPath/SSPath) www.sgpath.chrepresented by:Prof. Dr. med. Gieri Cathomas, PresidentInstitut für PathologieKantonsspital Baselland, Mühlemattstraße 11, CH-4410 Liestal

Organizing CommitteeGieri Cathomas, Liestal, Switzerland (President of the SGPath/SSPath)Gerald Höfler, Graz, Austria (President elect of the OEGPath/IAP Austria)Christa Freibauer, Mistelbach, Austria (Secretary of the OEGPath/IAP Austria)Martin Klimpfinger, Vienna, Austria (President of the OEGPath/IAP Austria)Cord Langner, Graz, AustriaSigurd Lax, Graz (Past-President of the OEGPath/IAP Austria)Laurence De Leval, Lausanne, SwitzerlandZsuzsanna Varga, Zürich, Switzerland (Secretary/Treasurer of the SGPath/SSPath)Inti Zlobec, Bern, Switzerland

Scientific CommitteeGieri Cathomas, Liestal, Switzerland (President of the SGPath/SSPath)Joachim Diebold, Luzern, SwitzerlandGerald Höfler, Graz, Austria (President elect of the OEGPath/IAP Austria)Ulrike Gruber-Mösenbacher, Feldkirch, AustriaChrista Freibauer, Mistelbach, Austria (Secretary of the OEGPath/IAP Austria)Martin Klimpfinger, Vienna, Austria (President of the OEGPath/IAP Austria)Paul Komminoth, Zürich, SwitzerlandOskar Koperek, Vienna, AustriaCord Langner, Graz, AustriaSigurd Lax, Graz (Past-President of the OEGPath/IAP Austria)Alessandro Lugli, Bern, Switzerland (Vice President of the SGPath/SSPath)Farid Moinfar, Linz, AustriaAurel Perren, Bern, SwitzerlandLaurence De Leval, Lausanne, SwitzerlandZsuzsanna Varga, Zürich, Switzerland (Secretary/Treasurer of the SGPath/SSPath)Inti Zlobec, Bern, Switzerland

5

General Information

Congress VenueTech Gate ViennaDonau-City-Straße 11220 Wienwww.techgate.atAll scientific sessions will take place at the Main Stage (ground floor). Thecommercial and poster exhibition area is located at the entrance area to theMain stage (ground floor). The presentations of the pulmonary pathology session on Thursday morning will be held in Room 1.2 (first floor).

LanguageThe official language of all scientific presentations is English.

Congress Secretariat - General InformationOffice of the Austrian Society of Pathology / IAP AustriaKarin LichteneggerTel.: +43 (0) 316 380 4400 / Fax.: +43 (0) 316 384329E-Mail: [email protected] Homepage www.pathology.at

Welcome DeskThe Welcome desk is located at the entrance of the Tech Gate and willoperate during the following hours:

Thursday, November 10 7:30 - 17:00 Friday, November 11 7:30 - 17:00 Saturday, November 12 8:00 - 12:00

Exhibition Management & SponsorshipInternational Exhibitions & AdvertisingMAW - Medizinische Ausstellungs- und WerbegesellschaftFreyung 6/3, 1010 WienTel.: +43 (0) 1 536 63-33, Fax: +43 (0) 1 535 60 16E-Mail: [email protected]

Information for SpeakersSpeakers are requested to submit their presentation before their session onCD-ROM or USB-Stick as MS PowerPoint.

Slide SeminarsThe seminars are accessible online via: http://www.iapaustria.comDeadline for submission of lists with suggested diagnoses: Monday, November 7, 12 p.m. CET.The handout will be available for download…..

6

General Information

PostersThe poster exhibition area is located at the entrance area to the main stage(ground floor).The poster session will take place on Friday, 11.11.2016 in the Foyer of theTech Gate building.

Authors are requested to put up posters on Friday morning before 10:00 andbe prepared to present their work during the poster visiting session from 12:15to 13:00. Posters should remain hanging until the end of the day.

Posters should be formatted as follows: 118,9 cm (height) x 84,1 cm (width)(so called DIN A0).

Poster PrizesThree prizes for best poster presentation and one prize for the best oral FreePaper Presentation will be handed out. The award ceremony will be held onSaturday, November 12th.

DFP FortbildungsprogrammThis event is registered for the advanced diploma education program (Diplom-Fortbildungs-Programm DFP) of the Austrian Medical Chamber. 25 DFP-points will be granted for the whole congress. 9 DPF-points for Thursday, November 10

10 DFP-points for Friday, November 116 DFP-points for Saturday, November 12

CME credits17 credits fort the whole congress8 credits per day (Thursday or Friday)1 credit for the Saturday lectureSlide seminar: 2 credits per slide seminarSubmission of slide seminar diagnoses: 2 credits per slide seminar

Certificate of AttendanceThe Certificate of Attendance will be handed out at the Welcome desk.

Coffee and CateringCoffee and catering will be served at the commercial exhibition areas. Allergenic ingredients will be declared in conformity with the EU-regulations.

WLAN ConnectionFree WLAN is permanent (“Multimedia Stage”)

7

* Please submit a written proof of resident status by the head of the department by email [email protected]

PaymentPayment via bank transfer not later than November 8, 2016 to: Recipient: OEGPath/IAP Austria; Kundratstraße 3, 1100 WienErste Bank; BLZ: 20111, Konto-Nr. 28133428704, IBAN: AT12 2011 1281 3342 8704, BIC: GIBAATWWXXX

Payment on site: Please notice that only cash (Euro) is taken.

Registration FeesPayment before

8th November 2016Registration

on site

ÖGPath/SGPath/IAP

Member

Consultant Pathologist € 160.– € 190.–

Resident* € 30.– € 50.–

Non-MemberConsultant Pathologist € 200.– € 250.–

Resident* € 70.– € 100.–

ÖGPath/SGPath/IAP

Member


Resident* € 20.– € 30.–

Thursday Friday Saturday

Non-Member


Resident* € 40.– € 50.–

Thursday Friday Saturday

Basics in Pathology (Thursday morning) Free of charge

Social Dinner (Friday)Consultant Pathologist € 50.–Resident € 20.–

En

tire

Meeti

ng

Day T

icket

General Information

Gala DinnerFriday, November 11 Palais TodescoKärntner Straße 511010 Wien Please notice prior registration is required. (See registration form).We appreciate your understanding, that the number of participants is limited.

Registration Fees

8

General Information

Hotels in ViennaWe kindly ask you to book your own hotel. There is a large number of hotelswithin different price categories available in Vienna. The Hotel Arcotel Kaiserwasser, the Hotel Melia Vienna and the Hotel NH Vienna are locatedclose to the Tech Gate. Hotels located near the metro U1 (red line) also provide a favorable geographical location to reach the Tech Gate.

Travel InformationHow to travel to the congress venue Tech Gate: The congress venue is reachableby metro U1 - red line. Please exit at the stop “Kaisermühlen - VIC”.

Parking by car at the venueComing from the city center by the Reichsbrücke, turn left at the first intersectiononto Platz der Vereinten Nationen (first light after the bridge). At the roundabout,take the exit for Donau-City-Straße. The entrance to the parking garage will beimmediately after this exit. A reduced rate for parking (€ 6.00) at Tech Gate is available at the Registration Office.ATTENTION: The reduced rate is only valid for the Tech Gate Garage

Travelling from and to Vienna Airport (Schwechat)Vienna International Airport is located 13 kilometers southeast of Vienna.Rapid Train Railway: Line S7 takes you directly from the airport to the center ofVienna (“Wien Mitte”, lines U3 and U4). The price for a one-way ticket is € 3.60.City Airport Train (CAT): The train runs every 30 minutes and takes 16 minutes. Tickets may be purchased online, from ticket machines at the airport/station or onboard.Taxi: Taxi fares to the conference venue are about € 40.00 and take around 25 minutes. There is a taxi stand outside the airport terminal. Nighttime fees areslightly higher.Bus: The Vienna Airport Lines operate several bus lines between Vienna andVienna International Airport.

9

General Information

Vienna Public TransportationVienna has an excellent PUBLIC TRANSPORT SYSTEM that is very effectiveand inexpensive. Tickets are available from machines at underground stations(maestro debit cards accepted), at newsstands, or at Vienna Transport Authority’sticket offices. Tickets bought in advance are cheaper and must be punched in a blue ticket-cancelling machine on the tram or bus, or at the barrier before boarding the underground train (www.wienerlinien.at).

10

Scie

ntif

ic P

rogr

am -

Ove

rvie

w

Th

urs

day,

10.1

1.2

016

Fri

day 1

1.1

1.2

016

Satu

rday 1

2.1

1.2

016

Sem

inarr

oo

m, 1st

Flo

or

Main

Sta

ge,

Gro

un

d f

loo

rM

ain

Sta

ge, G

rou

nd

flo

or

Main

Sta

ge, G

rou

nd

flo

or

8:45

– 9

:00

Welc

om

e8:

30 –

9:0

0Pr

edic

tive

Biom

arke

r Te

stin

g in

Lun

g C

ance

rSp

onso

red

lect

ure

by R

oche

8:30

– 8

:45

Biom

arke

r in

the

ther

apy

of

the

pulm

onar

y sq

uam

ous

cell

carc

inom

a, u

pdat

e fo

r EG

FR-a

ntib

ody

appl

icat

ion

Spon

sore

d le

ctur

e by

Lilly

9:00

– 1

0:30

Pu

lmo

nary

p

ath

olo

gy

Basic

path

olo

gy

of

the u

pp

er

gastr

oin

testi

nal

tract

Part

1

8:45

– 1

0:30

Sli

de s

em

ina

rT

hyro

id p

ath

olo

gy

incl

udin

g cy

tolo

gy

Neu

roen

docr

ine

tum

ors

of th

e lu

ngSp

onso

red

lect

ure

by N

ovar

tis

9:00

– 1

0:00

Up

date

of

gastr

oin

testi

nal

path

olo

gy

Part

110

:00

– 10

:30

Cof

fee

Brea

k10

:30

– 11

:00

Cof

fee

Brea

k10

:30

– 11

:45

Up

date

of

gastr

oin

testi

nal

path

olo

gy

Part

2

10:3

0 –

11:0

0H

on

ora

ry M

em

be

rsh

ip a

nd

Aw

ard

pre

se

nta

tio

n

cere

mo

ny

11:0

0 –

12:0

0Pe

rson

aliz

ed

imm

une-

onco

logy

- be

nefit

an

d po

tent

ial o

f PD

-L1-

test

ing

Spon

sore

d le

ctur

e by

MSD

T790

M te

stin

g in

pla

sma

Spon

sore

d le

ctur

e by

As

tra Z

enec

a

Basic

path

olo

gy

of

the u

pp

er

gastr

oin

testi

nal

tract

Part

2

11:0

0 –

11:3

0C

offe

e Br

eak

11:3

0 –

13:3

0

Sli

de s

em

ina

rB

rea

st

path

olo

gy

12:0

0 –

12:3

0Lu

nch

Brea

k11

:45

– 13

:00

Lunc

h br

eak

incl

udin

gp

oste

r p

resen

tati

on

(f

rom

12:1

5)

13:0

0 –

15:0

0B

reast

path

olo

gy

Part

1

13:0

0 –

13:3

0L

iqu

id B

iop

sy

13:3

0 –

14:1

5O

ral

Fre

e p

ap

ers

From

13:

30Af

tern

oon

snac

k

En

d o

f co

nfe

ren

ce

14:1

5 –

15:4

5E

nd

ocri

ne p

ath

olo

gy

Part

115

:00

– 15

:30

Cof

fee

Brea

k15

:30

– 16

:00

Ora

l F

ree p

ap

ers

16:0

0 –

18:0

0B

reast

path

olo

gy

Part

2

15:4

5 –

16:1

5C

offe

e Br

eak

16:1

5 –

17:1

5E

nd

ocri

ne p

ath

olo

gy

Part

2

17:1

5 –

17:4

5K

eyn

ote

lectu

re

Imm

un

oth

era

py

18:0

0 –

18:3

0Br

eak

18:0

0 –

19:3

0G

ener

al A

ssem

bly/

SGPa

thG

ener

al A

ssem

bly/

ÖG

Path

18:3

0 –

19:3

0M

eetin

g of

the

Dire

ctor

sSG

Path

Scientific Program

11

Thursday, 10th November 2016

7:30 – 8:30 Registration

8:45 – 9:00 Opening G. Cathomas (Liestal), M. Klimpfinger (Wien)

9:00 – 10:30 Basic pathology of the upper gastrointestinal tract - Part 1Chair: G. Cathomas (Liestal), M. Klimpfinger (Wien)

9:00 – 9:30 Barrett’s esophagus - the basicsF. Offner (Feldkirch)

9:30 – 10:00 Pathology of the small intestineM. Klimpfinger (Wien)

10:00 – 10:30 Infections of the upper gastrointestinal tractG. Cathomas (Liestal)

10:30 – 11:00 Coffee break

11:00 – 12:00 Basic pathology of the upper gastrointestinal tract - Part 2Chair: G. Cathomas (Liestal), M. Klimpfinger (Wien)

11:00 - 11:30 Benign mimics of gastric cancerF. M. Carneiro (Porto)

11:30 – 12:00 Molecular pathology of the upper gastrointestinal tract: A primerT. Grob (Bern)

12:00 – 13:00 Lunch break

13:00 – 15:00 Breast pathology - Part 1Chair: G. Singer (Baden) S. Lax (Graz)

13:00 – 13:30 Special Types of Breast Cancer: prognostic significance C. Quinn (Dublin)

13:30 – 13:50 Quality assurance in grading of breast cancerT. Decker (Neubrandenburg)

13:50 – 14:10 Quality assurance in HER2 status in breast cancerJ. Rüschoff (Kassel)

14:10 – 14:30 Quality assurance in Ki-67 assessment in breast cancerH. Kreipe (Hannover)

14:30 – 15:00 Triple negative and basal like breast cancerJ. S. Reis-Filho (New York)


12


15:30 – 16:00 Oral free papers 1Chair: F. Offner (Feldkirch), I. Zlobec (Bern)

J.R. Gsponer1, D.C. Müller1, C. Quintavalle1, T. Lorber1, D. Juskevicius1, T. Zellweger4, M.T. Barrett3, C.A. Rentsch2,L. Bubendorf1, C. Ruiz1

1Institute for Pathology, University Hospital Basel, Basel, Switzerland2Department of Urology, University Hospital Basel, Basel, Switzerland3Department of Research, Mayo Clinic Arizona, USA4Department of Urology, St. Claraspital, Basel, SwitzerlandSubclonal analysis of prostate cancer identifies FKBP4as a driver and a therapeutic target in the progression tocastration resistance

M. Kreutzfeldt1, P. Tsantoulis2, L. Rubbia Brandt1, S. Tejpar3,A. Roth2, M. Delorenzi4, F. Bosman5, P. Yan5, D. Merkler1, T. McKee1

1Clinical Pathology Service & Dept of Pathology & Immunology,Geneva, Switzerland

2Oncology Service, Geneva University Hospitals, Geneva, Switzerland 3Molecular Digestive Oncology, KU Leuven, Leuven, Belgium4Swiss Institute for Bioinformatics, Lausanne, Switzerland 5Unversity of Lausanne, Lausanne, Switzerland Colon cancer: computer-assisted quantitative immuno-histochemical analysis improves RNA expression basedprognostic score.

A. Roberti1, M.P. Dobay2, B. Bisig1, D. Vallois1, C. Boéchat1,E. Missiaglia1,2, P. Gaulard3, L. de Leval11Institute of Pathology, CHUV, Lausanne, Switzerland2Swiss Institute of Bioinformatics, Lausanne, Switzerland3Department of Pathology, Hôpital Henri Mondor, Créteil, FranceType II enteropathy-associated T-cell lymphoma featuresa unique genomic profile with highly recurrent SETD2alterations

Scientific Program

13


16:00 – 18:00 Breast pathology - Part 2Chair: Z. Varga (Zurich), F. Moinfar (Linz)

16:00 – 16:30 Neoadjuvant chemotherapy and its current aspects inbreast cancerF. Symmans (Houston)

16:30 – 16:50 New treatment options in receptor-positive breast cancerM. Gnant (Wien)

16:50 – 18:00 Multigene tests in breast cancer

16:50 – 17:05 Oncotype DX recurrent score and evidence for prognosisand prediction at breast cancerO. Gluz (Mönchengladbach)

17:05 – 17:20 Mammaprint and evidence for prognosis and prediction atbreast cancerH. Horlings (Amsterdam)

17:20 – 17:35 Endopredict and evidence for prognosis and prediction atbreast cancerZ. Bago-Horvath (Wien)

17:35 – 17:50 Pam50 and evidence for prognosis and prediction at breastcancerK. Sotlar (Salzburg)

17:50 – 18:00 Discussion

18:30 – 19:30 Meeting of the Directors SGPathSeminar room, 1st floor

Scientific Program

Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, 1121 Vienna, Phone 01/801 05-0, Fax 01/804 08 23

Every year 14 million people get cancer.We try to fight this disease at its roots.www.boehringer-ingelheim.at

Value through Innovationalue tVVa ionatough Innovalue thr

y te trWy year 14 million people get cerEv

ight this disease at its ro fy ty year 14 million people get c

oots.ight this disease at its r.ancerr.y year 14 million people get c

www.boehringer-ingelheim.at

y twww.boehringer-ingelheim.at

ight this disease at its r

Dr. Boehringer-Gasse 5-11, 1121 Vienna, Phone 01/801 05-0, Fax 01/804 08 23Dr. Boehringer-Gasse 5-11, 1121 Vienna, Phone 01/801 05-0, Fax 01/804 08 23Boehringer Ingelheim RCV GmbH & Co KG,

Dr. Boehringer-Gasse 5-11, 1121 Vienna, Phone 01/801 05-0, Fax 01/804 08 23Boehringer Ingelheim RCV GmbH & Co KG,

Dr. Boehringer-Gasse 5-11, 1121 Vienna, Phone 01/801 05-0, Fax 01/804 08 23

15

Friday, 11th November 2016

8:30 – 9:00 Predictive Biomarker Testing in Lung Cancer Sponsored lecture by RocheW. Jochum (St. Gallen)

9:00 – 10:00 Update of gastrointestinal pathology - Part 1Chair: L. Terracciano (Basel), Ch. Wittekind (Leipzig)

9:00 – 9:20 Barrett’s esophagus: Morphogenesis and molecular pathology C. Langner (Graz)

9:20 – 9:40 Budding consensus for colorectal cancerA. Lugli (Bern)

9:40 – 10:00 Molecular pathology update in colorectal cancerI. Zlobec (Bern)


10:30 – 11:45 Update of gastrointestinal pathology - Part 2Chair: C. Langner (Graz), L. Rubbia-Brandt (Genf)

10:30 – 10:55 Gastric adenocarcinoma and proximal polyposis of thestomach (GAPPS)F. M. Carneiro (Porto)

10:55 – 11:20 What’s new in GIST?B. Liegl-Atzwanger (Graz)

11:20 – 11:45 TNM 8 - What is new for the gastrointestinal tract?Ch. Wittekind (Leipzig)

11:45 – 13:00 Lunch break

12:15 – 13:00 Poster presentationA. Chott (Wien) and R. Caduff (Zürich)M. Frattini (Locarno) and B. Liegl-Atzwanger (Graz)

13:00 – 13:30 Liquid biopsyChair: I. Zlobec (Bern)A. Bardelli (Torino)

Scientific Program

16


13:30 – 14:15 Oral free papers - 2C. Langner (Graz), L. De Leval (Lausanne)

B. Dislich1, A. Stein1, C.A. Seiler2, D. Kröll2, S. Berezowska1,I. Zlobec1, J. Galvan1, R. Langer1

1Institute of Pathology, University of Bern, Bern, Switzerland2Department of Visceral Surgery and Medicine, Inselspital University Hospital Bern, Bern, SwitzerlandPD-L1 expression in esophageal adenocarcinomas:comparison between primary tumors and metastases

M. Hader1, W. Pokieser1, H. Schuster², G. Mostbeck², A. Chott11Institute for Pathology and Microbiology, Wilhelminenspital,Vienna, Austria

²Department for Radiology, Wilhelminenspital, Vienna, AustriaCore needle biopsies: Our experiences in the diagnosticsof lymphoma

T. Menter1,2, D. Juskevicius1, M. Alikian2, J. Steiger3, S. Dirnhofer1, K. N. Naresh2, A. Tzankov1

1Institute of Pathology, University Hospital Basel, Basel,Switzerland

2Department of Cellular and Molecular Pathology, Hammersmith Hospital Campus, Imperial College Healthcare NHS Trust, London, UK

3Clinic for Transplantation Immunology and Nephrology,University Hospital Basel, Basel, Switzerland

Genetic profiling of monomorphic post-transplant lymphoproliferative B-cell disorders

K. Oehl1, B. Vrugt1, U. Wagner1, A.J. Christiansen1, M. Meerang2, M.B. Kirschner2, W. Weder2, I. Opitz2, P.J. Wild1

1University Hospital Zurich, Institute of Surgical Pathology,Zurich, Switzerland

2University Hospital Zurich, Division of Thoracic Surgery,Zurich, Switzerland

Tracking the clonal origin and chemotherapy resistanceof malignant pleural mesothelioma

Scientific Program

17

Scientific Program


14:15 – 16:00 Endocrine Pathology - Part 1Chair: A. Perren (Bern), O. Koperek (Vienna)

14:15 – 14:45 WHO classification: the old and the new / an update on thyroid pathologyP. Komminoth (Zürich)

14:45 – 15:15 Non-invasive follicular tumors (NIFT): from empirical evidence to scientific factsM. Sobrinho-Simões (Porto)

15:15 – 15:45 Aggressive thyroid carcinomas: gray zones between widelyinvasive, poorly differentiated and anaplastic carcinomasM. G. Papotti (Torino)


16:15 – 17:15 Endocrine Pathology - Part 2Chair: A. Perren (Bern), O. Koperek (Vienna)

16:15 – 16:45 The Bethesda system for thyroid cytology: principles, applications and caveatsB. Cochand-Priollet (Paris)

16:45 – 17:15 Molecular markers in thyroid cytology and histology: molecular classification, diagnostic and predictive rolestodayM. Dettmer (Bern)

17:15 – 17:45 “Immunotherapy: What the Pathologists should know”Chair: G. Cathomas (Liestal)P. Hofman (Nice)

18:00 – 19:30 General Assembly of the Austrian Society of PathologyMartin Klimpfinger and Christa Freibauer, Austria(Main Stage, Ground floor)

18:00 – 19:30 General Assembly of the Swiss Society of PathologyGieri Cathomas and Zsuzsanna Varga, Switzerland(Seminarroom, 1st floor)

18

Scientific Program

Saturday, 12th November 2016

8:30 – 8:45 Biomarker in the therapy of the pulmonary squamous cellcarcinoma, update for EGFR-antibody application Sponsored lecture by LillyG. Hutarew (Salzburg)

8:45 – 10:30 Slide seminar - Thyroid pathology including cytologyChair: P. Komminoth (Zürich), O. Koperek (Wien)

Case presentation M. Sobrinho-Simões (Porto), O. Koperek (Wien), M. Dettmer (Bern), S. Lax (Graz), A. Perren, (Bern) M. Bongiovanni (Lausanne)

10:30 – 11:00 Honorary membership and award presentation ceremony


11:30 – 13:30 Slide seminar - Breast pathologyChair: M. Körner (Ittingen), T. Decker (Neubrandenburg)

Case presentationF. Moinfar (Linz) J. Diebold (Luzern) S. Lax (Graz) Z. Varga (Zürich)

From 13:30 Afternoon snack

End of conference

19

Scientific Program

WG-Pulmonary Pathology, Thursday 10th November 2016Parallel-session, seminarroom 1.2, 1st Floor

9:00 – 12:00 WG Pulmonary PathologyChair: U. Gruber-Mösenbacher (Feldkirch), U. Setinek (Wien)

9:00 – 10:00 Preanalytics in the era of molecular pathology-thoracictumors:

9:00 – 9:20 Techniques of biopsy - how can we gain optimal tissue forpredictive and prognostic diagnosis?A. Valipour (Wien)

9:20 – 9:40 Histology or cytology? What do pathologists need for tumortyping and molecular diagnosis?D. Krenbek (Wien)

9:40 – 10:00 What can we gain from cellular and cell free liquids for predictive diagnostics?S. Savic Prince(Basel)

10:00 – 11:30 Diagnostics and targets neuroendocrine tumors

10:00-10:30 Satellite symposium Neuroendocrine tumors of the lung: what the clinicianwants to know from the pathologist - an interdisciplinary dialogueA. Perren (Bern), M. Raderer (Wien) Sponsored lecture by Novartis Pharma


11:00 – 11:15 Pitfalls and differential diagnoses of neuroendocrine tumorsin small biopsies G. Hutarew (Salzburg)

11:15 - 11:45 Personalized immune-oncology benefit and potential of PD-L1-testingD. Krenbek (Wien)Sponsored lecture by MSD

11:45 – 12:00 T790M testing in plasmaK. Kashofer (Graz), H. Popper (Graz)Sponsored lecture by Astra Zeneca

20

Speakers and Chairs

Bago-Horvath Zsuzsanna, Dr., Klinisches Institut für Pathologie, AKH Wien / Medizinische Universität Wien, Wien

Bardelli Alberto, Assoc. Prof. Dr., Dipartimento di Oncologia, Università di Torino, Torino, Italia

Bongiovanni Massimo, Assoc. Prof. Dr., Pathology, University of Lausanne, Cytopathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Schweiz

Caduff Rosemarie, Prof. Dr., Pathologie, Universitätsspital Zürich, Zürich, Schweiz

Carneiro Maria Fatima, Prof. Dr., Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal

Cathomas Gieri, Prof. Dr., Institut für Pathologie, Kantonsspital BaselLand, Liestal, Schweiz

Chott Andreas, Prim. Univ.-Prof. Dr., Institut für Pathologie und Mikrobiologie, Wilhelminenspital, Wien

Cochand-Priollet Béatrix, Dr., Department of Cytology and Pathology, Lariboisière Hospital, Paris, Frankreich

Decker Thomas, Dr., Institut für Pathologie Neubrandenburg, Dietrich-Bonhoeffer-Klinikum, Neubrandenburg, Deutschland

De Leval Laurence, Prof. Dr., Institute of Pathology, University of Lausannne, Lausanne, Switzerland

Dettmer Matthias, OA Dr., Institut für Pathologie, Universität Bern, Bern, Schweiz

Diebold Joachim, Prof. Dr., Pathologisches Institut, Luzerner Kantonsspital, Luzern, Schweiz

Frattini Milo, Dr. PhD, Institute of Pathology Locarno, Locarno, SchweizGluz Oleg, Dr., Evang. Krankenhaus Bethesda Brustzentrum,

Mönchengladbach, DeutschlandGnant Michael, Univ. Prof. Dr., Universitätsklinik für Chirurgie, AKH Wien /

Medizinische Universität Wien, WienGrob Tobias, PD Dr. med. Dr. phil., Institut für Pathologie, Universität Bern,

Bern, SchweizGruber-Mösenbacher Ulrike, Dr., FeldkirchHofman Paul, Prof. Dr., Laboratoire de pathologie Clinique et

experimentale, Centre Hospitalier Universitaire de Nice, Nice, France

21

Horlings Hugo, MD, PhD., National Cancer Institute, Amsterdam, The Netherlands

Hutarew Georg, OA Dr., Pathologisches Institut, Universitätsklinikum Salzburg, LKH Salzburg, Salzburg

Jochum Wolfram, Prof. Dr., Institut für Pathologie, Kantonsspital St. Gallen, St. Gallen, Schweiz

Kashofer Karl, Dr., Institut für Pathologie, Medizinische Universität Graz,Graz

Klimpfinger Martin, Prim. Univ. Prof. Dr., Pathologisch-BakteriologischesInstitut, Kaiser-Franz-Josef-Spital / SMZ Süd, Wien

Komminoth Paul, Prof. Dr., Institut für Pathologie, Stadtspital Triemli Zürich, Zürich, Schweiz

Körner Meike, PD. Dr., Pathologie Langgasse, Ittingen, Schweiz Koperek Oskar, Priv.-Doz. Dr., Klinisches Institut für Pathologie,

AKH Wien / Medizinische Universität WienKreipe Hans H., Prof. Dr., Institut für Pathologie, Medizinisches

Hochschule Hannover, Hannover, DeutschlandKrenbek Dagmar, Dr., Pathologisch-Bakteriologisches Institut,

Otto-Wagner-Spital, WienLangner Cord, Univ.-Doz. Dr., Institut für Pathologie,

Medizinische Universität Graz, GrazLax Sigurd, Prim. Univ.-Prof. Dr., Institut für Pathologie,

LKH Graz Süd-West, GrazLiegl-Atzwanger Bernadette, Assoc. Prof. Dr., Institut für Pathologie,

Medizinische Universität Graz, GrazLugli Alessandro, Prof. Dr., Institut für Pathologie, Universität Bern, BernMoinfar Farid, Prim. ao. Univ.-Prof. Dr., Institut für Pathologie,

Barmherzige Schwestern Linz, LinzOffner Felix, Prim. Univ.-Prof. Dr., Institut für Pathologie, LKH Feldkirch,

Universitäres Lehrkrankenhaus, FeldkirchPapotti Mauro Giulio, Prof. Dr., Anatomia patologica, Università di Torino,

Torino, ItaliaPerren Aurel, Prof. Dr., Institut für Pathologie, Universität Bern, Bern,

Schweiz Popper Helmut, ao. Univ.-Prof. Dr., Institut für Pathologie,

Medizinische Universität Graz, Graz

Speakers and Chairs

Power Your Clinical Genomic Tests with Sophia DDM®

Collective AI for Data-Driven Medicine

sophiagenetics.com @SophiaGenetics

Accurate SNP and INDEL Detection

Superior CNV Resolution

Advanced Variant Annotation

GP

cienomGo Yrewo

wistse Tcinil Cruo

ht wialc

SG

D DhiapocienomG

®MD wistse T

ht wi

AevitcelolC

nicdie MnevirD-ata Dro fI

en

cet DeLEDINP aNe StaruccA

noitcd nP a

nioutloesRN CoreripuS

V

onitatnnoA

VdeancvdA

on

tanari

comenetics.sophiag

com @SophiaGenetics

@SophiaGenetics

23

Quinn Cecily, Prof. Dr., St. Vincent’s Hospital, UCD School of Medicine,Dublin, Irland

Raderer Markus, Univ.-Prof. Dr., AKH Wien, Universitätsklinik für InnereMedizin I, Klinische Abteilung für Onkologie, Wien

Reis-Filho Jorge S., Dr. Phd, Memorial Sloan Kettering Cancer Center,New York, USA

Rubbia-Brandt Laura, Prof. Dr., Department of Pathology and Immunology, Université de Genève, Genève

Rüschoff Josef, Prof. Dr., Pathologie Nordhessen, Kassel, DeutschlandSavic Prince Spasenija, OA Dr., Universitätsspital Basel,

Molekulare Pathologie und Zytologie, Basel, SchweizSetinek Ulrike, OA Dr., SMZ Otto-Wagner-Spital,

Pathologisch-Bakteriologisches Institut, WienSinger Gad, Prof. Dr., Institut für Pathologie, Kantonsspital Baden,

Baden, SchweizSobrinho-Simões Manuel, Prof. Dr., Institute of Molecular Pathology and

Immunology, University of Porto, PortugalSotlar Karl, Prim. Univ.-Prof. Dr., Pathologisches Institut,

Universitätsklinikum Salzburg, LKH Salzburg, SalzburgSymmans W. Fraser, Prof. Dr., The University of Texas MD Anderson

Cancer Center, Houston, USATerracciano Luigi, Prof. Dr., Pathologie, Universitätsspital Basel,

Basel, SchweizValipour Arschang, Priv.Doz. Dr., Ordinationszentrum Döbling, WienVarga Zsuzsanna, Prof. Dr. Klinisches Institut für Pathologie,

Universitätsspital Zürich, Zürich, SchweizWittekind Christian, Prof. Dr., Institut für Pathologie, Universitätsklinikum

Leipzig, Leipzig, DeutschlandZlobec Inti, Prof. Dr., Institut für Pathologie, Universität Bern,

Bern, Schweiz

Speakers and Chairs

24

Poster exhibition 11th November

Poster Nr. 1

Tumor tracking of Non-Small Cell Lung Carcinoma (NSCLC) by ultra-deep sequencing of the entire mitochondrial genomeW. Amer1, E. Vassella2, C. Toth1, H. Eischeid1, U. Koitzsch1, A. Arens3, R.Büttner1, S.C. Schäfer1*, M. Odenthal1*

1Institute of Pathology, University Hospital of Cologne, Cologne, Germany and others

Poster Nr. 2

HMGA1 expression in human hepatocellular carcinoma correlates withpoor prognosis and promotes tumor growth and migration in in vitromodels.M. Andreozzi1, C. Quintavalle1, D. Benz1, L. Quagliata1, M. Matter1, D. Calabrese2, N. Tosti1, C. Ruiz1, F. Trapani1, L. Tornillo1, A. Fusco3,4, M.H. Heim2, C.K.Y. Ng1, P. Pallante1,3, L.M. Terracciano1, S. Piscuoglio1

1Institute of Pathology, University Hospital Basel, Basel, Switzerland and others

Poster Nr. 3

Histological evaluation of peritoneal samples in recurring tubo-ovariancarcinomas treated by Pressurized Intra-Peritoneal Aerosol Chemotherapy(PIPAC) for recurring tubo-ovarian carcinoma: A one-center experiencein 13 patients (CHUV, Lausanne, Switzerland)J.L. Barras1, A. Wolfer2, J. Mathis3, P. Mathevet3, M. Hubner4, M. Fiche1

Departments of Pathology1, Oncology2, Gynecology3 and Surgery4, CHUV Lausanne,Lausanne, Switzerland

Poster Nr. 4

NGS Guidelines for diagnostic use: The Basel approach using the IonTorrent platformM. Bihl, L. Quagliata, L. Terracciano, S. HöllerInstitute of Pathology, Diagnostic Molecular Pathology, University Hospital Basel,Basel, Switzerland

Poster Nr. 5

Comparison of human papillomavirus status in cytological smearsusing AnyplexTM II HPV28 (Seegene) and INNO-LiPA® (Fujirebio®) tests.M. Bihl, S. Hoeller, A. Foerster, T. Dietsche, S. Tschumi, L. TerraccianoInstitute of Pathology, Diagnostic Molecular Pathology, University Hospital Basel,Basel, Switzerland

Poster Nr. 6

Immunohistochemical detection of PAX/FOXO1 fusion protein in alveolarrhabdomyosarcomaP. K. Bode1*, M. Wachtel2*, J. Khan3, L. Cao3, P. S. Meltzer3, Ch. Vokuhl4, U. Camenisch1, H.L. Khov1, B. Bode1, B. W. Schäfer2

1 Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland and others

25


Poster Nr. 7

High PDL1 expression levels may influence disease outcome inmyeloma patientsA. Brunner1, E. Reichinger2, R. Weger2,3, W. Willenbacher2, E. Gunsilius2

1Department of Pathology, Medical University of Innsbruck, Innsbruck, Austria andothers

Poster Nr. 8

Human papillomavirus types in cervical intraepithelial neoplasia inSwitzerland: the CIN3+plus studyJ. Diebold1 , D. Egli-Gany2, A. Häfliger2, A. Spaar3, V. Masserey Spicher3, R. Heusser4, P. Petignat5, B. Frey Tirri6, R. Sahli7, N. Low2 for the CIN3+plusstudy group1Institute of Pathology, Lucerne Cantonal Hospital, Lucerne, Switzerland and others

Poster Nr. 9

ROR1: a candidate for new molecular targeted therapies in lung adenocarcinomaS. Epistolio1, V. Martin1, F. Molinari1, M. Bongiovanni1, L. Wannesson2, J. Barizzi1, L. Mazzucchelli1, M. Frattini11Laboratory of Molecular Pathology, Institute of Pathology, Locarno, Locarno, Switzerland and others

Poster Nr. 10

A faster and more sensitive assay for BRAF characterizationS. Epistolio1, M. Guldmann-Christensen4, S. Hamilton-Dutoit4, T. Steiniche4,M.H. Kyneb3, M. Boergesen2, C. Andersen2, A. Riva1, L. Mazzucchelli1, T.Y. Wolff4, J.Lorenzen3, U.B. Christensen2, M. Frattini11Laboratory of Molecular Pathology, Institute of Pathology, Locarno, Locarno, Switzerland and others

Poster Nr. 11

Targeted mutational analysis of a diffuse large B-cell lymphoma cohortidentifies CREBBP and SOCS1 mutations as an independent prognosticfactorD. Juskevicius, D. Jucker, S. Dirnhofer, A. TzankovInstitute of Pathology, University Hospital Basel, Basel, Switzerland

Poster Nr. 12

The diffuse extent of peritubular capillaritis in late antibody mediatedrejection is associated with more severe chronic allograft damage.N. Kozakowski1, F. Eskandary2, H. Herkner3, R. Oberbauer2, G. Bond2, H. Regele1, G.A. Böhmig2 and Ž. Kikić2

1Clinical Institute of Pathology, Medical University Vienna, Vienna, Austria and others

26


Poster Nr. 13

Revealing the genomic evolution from squamous cell carcinoma of thelung to metastasisA. Krause1, T. Lorber1, V. Perrina1, T. Dietsche1, M. T. Barrett2, C. Ruiz1, L. Bubendorf2

1Institute for Pathology, University Hospital of Basel, Basel, Switzerland and others

Poster Nr. 14

Comparison of two monoclonal antibodies for PD-L1 expression in non-small cell lung cancerD. Krenbek1, U. Setinek1, C. Jarius1, B. Weidinger1, S. Holzer2, M. Hochmair2,A. Chott11Department of Pathology, Otto Wagner Hospital, Vienna, Austria and others

Poster Nr. 15

Assessment of predictive biomarkers in cancer tissues using micro-immunohistochemistry followed by DNA sequencingA.L. Leblond1, D. Machiraju1,E. Bianchi1, M. Rechsteiner1, P. Wild1, A. Jones2,D. Heintze2, A.T. Ciftlik2, A. Soltermann1

1Department of Pathology and Molecular Pathology, University Hospital, Zurich,Switzerland and others

Poster Nr. 16

Lymph node retrieval in colorectal cancer: determining factors andprognostic significanceN. Max1, J. Betge2, M.J. Pollheimer1, R.A. Lindtner3, L. Harbaum4, C. Langner1

1Institute of Pathology, Medical University of Graz, Graz, Austria and others

Poster Nr. 17

Diagnostic utility of LEF1 immunohistochemistry in small B cell lymphomasT. Menter1,2, P. Trivedi1, R. Ahmad 1, R. Flora 1, S. Dirnhofer2, A. Tzankov2, K. N. Naresh1

1Department of Pathology, Hammersmith Hospital Campus, Imperial College Healthcare NHS Trust, London, UK and others

Poster Nr. 18

Next-generation sequencing: validation and use in cancer diagnosticsE. Missiaglia1, B. Bisig1, S. Rappo1, K. Homicsko2, O. Michielin2, L. de Leval11Institut de Pathologie, Centre hospitalier universitaire vaudois (CHUV), Lausanne,Switzerland and others

27


Poster Nr. 19

Expression analysis of LC3B and p62 indicates intact activated autophagy is associated with an unfavorable prognosis in colon cancer M. Niklaus1, O. Adams1, S. Berezowska1, I. Zlobec1, U. Nitsche2, J. Slotta-Huspenina3, M. P. Tschan1, R. Langer1

1Institute of Pathology, University of Bern, Bern, Switzerland and others

Poster Nr. 20

Lack of CDX2 Expression - Marker of Aggressive Biology in ColorectalCancer?M.J. Pollheimer1, N. Max1, R.A. Lindtner2, L. Harbaum3, C. Langner1

1Institute of Pathology, Medical University of Graz, Graz, Austria and others

Poster Nr. 21

High mobility group A1 overexpression modulates growth of humancholangiocarcinomaC. Quintavalle1, K. Burmeister1, S. Piscuoglio1, L. Quagliata1, E. Karamitopoulou2, R. Sepe3, A. Fusco3,4, J.B. Andersen5, L.M. Terracciano1,P. Pallante1,3, M.S. Matter1

1Institute of Pathology, University of Basel, Basel, Switzerland and others

Poster Nr. 22

SOX9 expression is associated with better clinical outcome in patientswith hepatocellular carcinomaG. Richtig1, A.M. Aigelsreiter2, C. Lackner3, G. Höfler3, M. Pichler4, A. Aigelsreiter3

1Institute of Experimental and Clinical Pharmacology, Medical University of Graz,Graz, Austria and others

Poster Nr. 23

HNF1b: a reliable marker of yolk sac tumors A.L. Rougemont, J.C. TilleDivision of Clinical Pathology, Geneva University Hospitals, Geneva, Switzerland

Poster Nr. 24

Autoimmune gastritis and enterochromaffin-like cell hyperplasia in childrenC. Saglietti1, A. Nydegger2, V. Schneider1, A. Karpate1, C. Sempoux1

1Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland and others

Poster Nr. 25

Inflammatory hepatocellular adenoma with focal b-catenin mutationJ. Saldarriaga1, B. Bisig1, G. Couchy2, C. Castain3, J. Zucman-Rossi2,4, C. Balabaud5, P. Bioulac-Sage3,5, C. Sempoux1

1Institute of Pathology, CHUV, Lausanne, Switzerland and others

28


Poster Nr. 26

Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis inglioblastoma, IDH-wildtypeE. Sartori1, R. Langer1, E. Vassella1, E. Hewer1, P. Schucht2, I. Zlobec1, S. Berezowska1


Poster Nr. 27

Microvessel density and VEGF in pancreatic neuroedocrine tumoursA.M. Schmitt, I. Marinoni, S. Naim, S. Pasquinelli, I. Centeno, A. PerrenInstitute of Pathology, University of Bern, Bern, Switzerland

Poster Nr. 28

Recovery of pure cell populations from archived formalin-fixed paraffin-embedded tissue for DNA and RNA analysisL. Sokol1, K. Seiler2, S. Zahnd1, V. Kölzer3, A. Lugli1, I. Zlobec1


Poster Nr. 29

Tularemia: More frequent than expected.M. Stoll1, A. Graber1, P. Graber2, G. Cathomas1

1Institute of Pathology, Kantonsspital Baselland, Liestal, Switzerland

Poster Nr. 30

Intraductal oncocytic papillary neoplasm arising in accessory pancreatic ductJ. Strobl1, T. Mayrhofer2, G. Höfler3, H. Immervoll11Department of Pathology, LKH Horn, Horn, Austria and others

Poster Nr. 31

Genetic alteration in urothelial carcinoma: comparison between uppertract and bladder origin.J.C. Tille1, G. Cancel-Tassin2, O. Cussenot3, E. Comperat41Service of Clinical pathology, Geneva University Hospitals, Geneva, Switzerland andothers

Poster Nr. 32

The role of HMGA1 protein in gastroenteropancreatic neuroendocrinetumorsN. Tosti1, C. Quintavalle1, S. Piscuoglio1, P. Pallante1,2, L. M. Terracciano1

1Institute of Pathology, University Hospital of Basel, Basel, Switzerland and others

29


Poster Nr. 33

Autopsies: tissue banking for molecular analyses?C.-Y. Tsai, J. Saldarriaga, E. Missiaglia, B. Bisig, S. RotmanUniversity Institute of Pathology, CHUV, Lausanne, Switzerland

Poster Nr. 34

Role of ROS1 immunocytochemistry on cytological specimens in patients with non-small cell lung cancerT. Vlajnic, S. Savic, L. BubendorfInstitute of Pathology, University Hospital Basel, Basel, Switzerland

Poster Nr. 35

Cardiac angiosarcoma with uncommon KRAS mutation mimicking sarcoidosisM. Wittersheim1, B. Böll2, A. Shimabukuro-Vornhagen2, C. Heydt1, R. Castiglione1, T. Blau3, H. ten Freyhaus4, A.M. Schultheis1, R. Büttner1, S.C.Schäfer1

1Institute of Pathology, 2Department of Internal Medicine I, 3Institute of Neuropatho -logy, 4Department of Internal Medicine III, Heart Center; University Hospital ofCologne, Cologne, Germany

Poster Nr. 36

Existence of cytokeratin/vimentin double-positive cells at the invasion frontof colorectal cancers: evidence of epithelial-mesenchymal transition?S. Zahnd, S.N. Meyer, L. Sokol, J. Galván, I. Centeno, A. Lugli, I. ZlobecInstitute for Pathology, University of Bern, Bern, Switzerland

Notes

30

Notes

31

Fachkurzinformation zu Umschlagseite 4Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisseüber die Sicherheit.

BEZEICHNUNG DES ARZNEIMITTELS: Lynparza 50 mg Hartkapseln Pharmakotherapeutische Gruppe: andere anti -neoplastische Mittel, ATC-Code: L01XX46. QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG: Jede Hartkapsel enthält 50 mg Olaparib. Sonstige Bestandteile Kapselinhalt Macrogolglycerollaurate (32 EO-Einheiten) (Ph.Eur.) KapselhülleHypromellose Titandioxid (E171) Gellan Gummi (E418) Kaliumacetat Drucktinte Schellack Eisen(II,III)-oxid (E172). ANWENDUNGSGEBIETE: Lynparza wird als Monotherapie für die Erhaltungstherapie von erwachsenen Patientinnen mit einemPlatin-sensitiven Rezidiv eines BRCA-mutierten (Keimbahn und/oder somatisch) high-grade serösen epithelialen Ovarial -karzinoms, Eileiterkarzinoms oder primären Peritonealkarzinoms angewendet, die auf eine Platin-basierte Chemotherapie ansprechen (vollständiges oder partielles Ansprechen). GEGENANZEIGEN: Überempfindlichkeit gegen den Wirkstoff odereinen der in Abschnitt 6.1 der Fachinformation genannten sonstigen Bestandteile. Stillen während der Behandlung und 1 Monatnach Einnahme der letzten Dosis (siehe Abschnitt 4.6 der Fachinformation). INHABER DER ZULASSUNG: AstraZeneca AB SE-15185 Södertälje Schweden. VERSCHREIBUNGSPFLICHT/APOTHEKENPFLICHT: Rezept- und apothekenpflichtig,wiederholte Abgabe verboten. Stand der Information: Dezember 2014. Informationen zu den Abschnitten besondere Warnhinweise und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungenmit anderen Arzneimitteln und sonstige Wechselwirkungen, Fertilität, Schwangerschaft und Stillzeit, Nebenwirkungen sowieden Gewöhnungseffekten sind der veröffentlichten Fachinformation (z.B. Austria Codex) zu entnehmen.

32

Gold Sponsor (as per printing date)

AstraZeneca

Main Sponsors

Sponsors and Exhibitors (as per printing date)

U3Printed by: ROBIDRUCK, A-1200 Vienna, Austria - www.robidruck.co.at

AstraZeneca

Positiver Test auf BRCA-Mutation.

Therapie mit Lynparza™.

Sie hat ein Ovarialkarzinom.

ERKENNEN.

ENTSCHEIDEN.

Erster PARP-Inhibitor bei BRCA mutiertem Ovarialkarzinom1–3

Verlängert das PFS um 6,9 Monate3

Erste zielgerichtete Erhaltungstherapie4–6

Orale, gut verträgliche Therapie4

ID 500701, 11/2014 Fachkurzinformation siehe Seite:

1 Weil MK et al. Curr Probl Cancer 2010; 35(1): 7-502 Ledermann J et al. N Engl J Med 2012; 366 (15): 1382–923 Ledermann J et al. Lancet Oncol 2014; 15 (8): 852–614 Fachinformation Lynparza™, Stand Dezember 2014

5 NCCN Clinical Practice Guidelines in Oncology – Ovarian cancer including fallopian tube cancer and primary peritoneal cancer 2013

6 Ledermann J et al. Ann Oncol 2013; 24 (6): 24–32 31

Path Herbst Prog 2016 - maw.co.at · Submission of slide seminar diagnoses: 2 credits per slide...

Documents

Transcript of Path Herbst Prog 2016 - maw.co.at · Submission of slide seminar diagnoses: 2 credits per slide...